Oncolytics Shares Jump 11% After Patent Extends Pelareorep Protection to 2044
ONCY•Shares of Oncolytics Biotech jumped 11% after the U.S. Patent and Trademark Office granted a patent protecting its Pelareorep manufacturing process until 2044. The company also has a method-of-use patent under review that could extend Pelareorep protection to 2046 and plans additional filings this year.
1. Patent Granted Through 2044
The U.S. Patent and Trademark Office granted Oncolytics Biotech a patent for its Pelareorep manufacturing process, securing exclusive production rights until 2044 and strengthening its commercial-scale immunotherapy capabilities.
2. Method-of-Use Patent Under Review
A method-of-use patent application for Pelareorep remains under review, potentially extending market exclusivity to 2046 if approved, and laying groundwork for expanded therapeutic use protection.
3. Ongoing Clinical Evaluations
Pelareorep is being evaluated in combination with chemotherapy and checkpoint inhibitors for metastatic gastrointestinal cancers, and has yielded encouraging results in pancreatic, metastatic breast, anal and colorectal cancer studies.
4. Expanded Patent Strategy
Oncolytics plans to file additional patent applications this year targeting new treatment settings, therapeutic uses and combination approaches to broaden intellectual property coverage.
